- Home
- CGEM
as 10-28-2025 9:35am EST
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 437.2M | IPO Year: | 2021 |
| Target Price: | $26.00 | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.52 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.68 - $17.50 | Next Earning Date: | 11-07-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Cullinan Oncology Inc. (CGEM)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Lynx1 Capital Management LP | CGEM | 10% Owner | Oct 17 '25 | Buy | $7.84 | 32,217 | $252,565.17 | 8,797,833 | |
| Lynx1 Capital Management LP | CGEM | 10% Owner | Oct 16 '25 | Buy | $8.86 | 150,000 | $1,328,250.00 | 8,797,833 | |
| Lynx1 Capital Management LP | CGEM | 10% Owner | Oct 15 '25 | Buy | $7.94 | 51,500 | $409,049.05 | 8,797,833 | |
| Lynx1 Capital Management LP | CGEM | 10% Owner | Oct 14 '25 | Buy | $7.59 | 15,032 | $114,047.78 | 8,797,833 |
Latest Cullinan Oncology Inc. News
CGEM Breaking Stock News: Dive into CGEM Ticker-Specific Updates for Smart Investing
PR Newswire
16 days ago
Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib in Patients with NSCLC with EGFR mutations and Active Brain Metastases at the ESMO Congress 2025
BioPharma Dive
5 months ago
Cullinan doubles down on bispecifics for autoimmune disease with Genrix deal
GlobeNewswire
5 months ago
Cullinan Therapeutics Licenses Rights to Velinotamig, a Clinical-Stage BCMA-Directed Bispecific T Cell Engager, from Genrix Bio for Development in Autoimmune Diseases
PR Newswire
5 months ago
Taiho Oncology and Cullinan Therapeutics Announce Pivotal REZILIENT1 Phase 1/2 Data Published in the Journal of Clinical Oncology
GlobeNewswire
5 months ago
Cullinan Therapeutics to Host Analyst and Investor Event at 2025 ASCO Annual Meeting and Participate in Jefferies 2025 Global Healthcare Conference
GlobeNewswire
5 months ago
Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT1 Trial of Zipalertinib at ASCO 2025
GlobeNewswire
6 months ago
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
GlobeNewswire
6 months ago
Cullinan Therapeutics to Initiate Study of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Sjögren’s Disease in the United States
Compare CGEM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CGEM Cullinan Oncology Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.